A Phase I Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2012

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Actual initiation date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 16 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top